The effects of luteolin on osteoclast differentiation, function in vitro and ovariectomy-induced bone loss
The effects of luteolin on osteoclast differentiation, function in vitro and ovariectomy-induced bone loss
复制标题
DOI：
10.1016/j.jnutbio.2009.11.002
复制
发表时间：
2011-01-01
影响因子：
5.6
通讯作者：
Kim, Shin-Yoon
中科院分区：
文献类型：
--
作者：
Kim, Tae-Ho;Jung, Ji Won;Kim, Shin-Yoon
黄酮类化合物是一组富含于植物中的多酚类化合物，已知其在卵巢切除（OVX）动物模型中可预防骨丢失。抑制破骨细胞分化和骨吸收被认为是治疗绝经后骨丢失的有效方法。木犀草素是一种植物黄酮类化合物，在体内和体外都具有有效的抗炎作用。在这项研究中，我们发现毛地黄黄酮显着降低骨髓单个核细胞和Raw 264.7细胞向破骨细胞的分化。木犀草素还抑制分化的破骨细胞的骨吸收活性。我们进一步研究了毛地黄黄酮对卵巢切除引起的骨丢失的影响，采用显微计算机断层扫描，生物力学测试和骨重建的血清标志物测定。与OVX对照组相比，OVX小鼠经口给予木犀草素（5和20 mg/kg/天）可显著增加股骨中骨小梁和皮质骨的骨矿物质密度和骨矿物质含量，并防止OVX手术引起的骨强度指数下降。血清生化标志物测定显示，毛地黄黄酮可预防OVX诱导的骨转换增加。这些数据有力地表明，毛地黄黄酮具有通过降低破骨细胞分化和功能来预防绝经后骨质疏松症中骨丢失的潜力。(C)2011 Elsevier Inc. All rights reserved.
Flavonoids, a group of polyphenolic compounds abundant in plants, are known to prevent bone loss in ovariectomized (OVX) animal models. Inhibition of osteoclast differentiation and bone resorption is considered as an effective therapeutic approach in the treatment of postmenopausal bone loss. Luteolin, a plant flavonoid, has potent anti-inflammatory properties both in vivo and vitro. In this study, we found that luteolin markedly decreased the differentiation of both bone marrow mononuclear cells and Raw264.7 cells into osteoclasts. Luteolin also inhibited the bone resorptive activity of differentiated osteoclasts. We further investigated the effects of luteolin on ovariectomy-induced bone loss using micro-computed tomography, biomechanical tests and serum markers assay for bone remodeling. Oral administration of luteolin (5 and 20 mg/kg per day) to OVX mice caused significant increase in bone mineral density and bone mineral content of trabecular and cortical bones in the femur as compared to those of OVX controls, and prevented decreases of bone strength indexes induced by OVX surgery. Serum biochemical markers assays revealed that luteolin prevents OVX-induced increases in bone turnover. These data strongly suggest that luteolin has the potential for prevention of bone loss in postmenopausal osteoporosis by reducing both osteoclast differentiation and function. (C) 2011 Elsevier Inc. All rights reserved.